Collectively, these data indicate that GLO1 could represent a therapeutic target in CF, such that increasing its activity might interfere with the pathogenic HIF1α–RAGE axis, and identify anakinra as a multifaceted anti-inflammatory molecule in CF. This evidence concerns the gene AGER and cystic fibrosis.